Mutations in
chromatin remodeling
immune checkpoint blockade
non-small cell lung cancer
response prediction
tumor mutation burden
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Jun 2022
06 Jun 2022
Historique:
received:
15
04
2022
revised:
24
05
2022
accepted:
01
06
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
Efficient predictive biomarkers are urgently needed to identify non-small cell lung cancer (NSCLC) patients who could benefit from immune checkpoint blockade (ICB) therapy. Since chromatin remodeling is required for DNA repair process, we asked whether mutations in chromatin remodeling genes could increase tumor mutational burden (TMB) and predict response to ICB therapy in NSCLC. Analysis of seven ICB-treated NSCLC cohorts revealed that mutations of three chromatin remodeling-related genes, including
Identifiants
pubmed: 35681795
pii: cancers14112816
doi: 10.3390/cancers14112816
pmc: PMC9179442
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Nat Rev Clin Oncol. 2019 Jul;16(7):425-441
pubmed: 30914826
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Nat Genet. 2018 Sep;50(9):1271-1281
pubmed: 30150660
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Nature. 2013 Oct 24;502(7472):489-98
pubmed: 24153302
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Cell Oncol (Dordr). 2020 Apr;43(2):321-333
pubmed: 31933152
Mol Oncol. 2012 Dec;6(6):611-9
pubmed: 23127546
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640
JAMA Oncol. 2019 Nov 1;5(11):1631-1633
pubmed: 31486842
Int J Biol Sci. 2021 Jan 30;17(3):670-682
pubmed: 33767579
Cancers (Basel). 2019 Aug 29;11(9):
pubmed: 31470674
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
J Clin Oncol. 2019 Apr 20;37(12):992-1000
pubmed: 30785829
J Clin Oncol. 2001 Mar 15;19(6):1734-42
pubmed: 11251004
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
J Immunother Cancer. 2018 Dec 4;6(1):141
pubmed: 30514390
Curr Mol Pharmacol. 2019;12(3):215-229
pubmed: 30767757
Trends Genet. 2020 Dec;36(12):936-950
pubmed: 32873422
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Trends Mol Med. 2007 Sep;13(9):373-80
pubmed: 17822959
Nat Cancer. 2021 Dec;1(12):1188-1203
pubmed: 33834176
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
J Pathol. 2020 Jan;250(1):19-29
pubmed: 31471895
Nat Rev Cancer. 2021 Jul;21(7):413-430
pubmed: 34002060
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Epigenomics. 2019 May;11(7):835-855
pubmed: 31150281
J Thorac Oncol. 2020 Sep;15(9):1535-1540
pubmed: 32450274
Curr Mol Med. 2017;17(8):527-540
pubmed: 29473504
Oncogene. 2012 Feb 9;31(6):776-86
pubmed: 21725364
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt B):306-327
pubmed: 29309830
Cancer Lett. 2019 Aug 28;458:56-65
pubmed: 31128216
Sci Transl Med. 2014 Mar 26;6(229):229ra42
pubmed: 24670686
Biochem Biophys Res Commun. 2012 Aug 17;425(1):45-50
pubmed: 22820187
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Cell Mol Life Sci. 2021 Mar;78(6):2517-2563
pubmed: 33263776
Cell. 2015 Sep 10;162(6):1257-70
pubmed: 26343581